GeoVax Labs (NASDAQ:GOVX) Earns “Outperform” Rating from Noble Financial

GeoVax Labs (NASDAQ:GOVX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Noble Financial in a research note issued on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the stock.

A number of other brokerages also recently issued reports on GOVX. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GeoVax Labs has a consensus rating of “Hold” and an average price target of $80.00.

Get GeoVax Labs alerts:

Check Out Our Latest Research Report on GeoVax Labs

GeoVax Labs Price Performance

Shares of GeoVax Labs stock traded up $0.00 during trading on Tuesday, hitting $0.43. The company’s stock had a trading volume of 212,837 shares, compared to its average volume of 2,041,380. GeoVax Labs has a 52 week low of $0.43 and a 52 week high of $17.74. The stock has a market cap of $3.20 million, a price-to-earnings ratio of -0.04 and a beta of 3.66. The stock has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $1.27.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last announced its earnings results on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.16) by $1.19. On average, equities analysts predict that GeoVax Labs will post -4.94 EPS for the current fiscal year.

About GeoVax Labs

(Get Free Report)

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.

Read More

• Five stocks we like better than GeoVax Labs
• A Sub-20 P/E on GOOGL? The Market May Be Missing Something
• SpaceX Defies Gravity With a Nasdaq-100 Double-Weighting Boost
• Navan’s Strong Quarter Meets an AI Spending Reality Check
• LightPath’s Defense Pivot Could Send Shares Higher

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.